Physician profile
Salimah Cumber
NPI 1912011966
$4,859.86
in general payments reported to CMS, 2019-2025
17 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $1,102 · 2021: $1,437 · 2022: $413 · 2023: $297 · 2024: $490 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $2,169.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $913.34 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $714.88 | 2019-2021 | |
| Abbvie INC. | $419.19 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $211.81 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $123.07 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $75.39 | 2019-2023 | Ozempic, Tresiba, Rybelsus |
| Amgen INC. | $47.70 | 2020-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $36.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $33.92 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.62 | 2019 | |
| Cipher Pharmaceuticals US LLC | $17.47 | 2025 | Natroba, Spinosad |
| Merck Sharp & Dohme LLC | $15.86 | 2019 | |
| Nevro Corp. | $15.34 | 2024 | Senza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.23 | 2020 | |
| Redhill Biopharma INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salimah Cumber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.